Meiji Yasuda Asset Management Co Ltd. decreased its holdings in Danaher Co. (NYSE:DHR – Free Report) by 3.3% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 30,309 shares of the conglomerate’s stock after selling 1,040 shares during the quarter. Meiji Yasuda Asset Management Co Ltd.’s holdings in Danaher were worth $6,957,000 at the end of the most recent reporting period.
A number of other institutional investors have also recently made changes to their positions in the business. Heck Capital Advisors LLC acquired a new position in shares of Danaher in the fourth quarter worth $27,000. Decker Retirement Planning Inc. acquired a new position in Danaher during the 4th quarter worth $31,000. Golden State Wealth Management LLC purchased a new stake in Danaher during the 4th quarter worth about $31,000. Strategic Financial Concepts LLC acquired a new stake in Danaher in the 4th quarter valued at about $31,000. Finally, Pineridge Advisors LLC boosted its stake in shares of Danaher by 63.3% in the 4th quarter. Pineridge Advisors LLC now owns 147 shares of the conglomerate’s stock valued at $34,000 after buying an additional 57 shares during the period. Institutional investors and hedge funds own 79.05% of the company’s stock.
Insider Buying and Selling at Danaher
In other Danaher news, SVP Brian W. Ellis sold 5,700 shares of the stock in a transaction dated Thursday, January 30th. The shares were sold at an average price of $224.13, for a total value of $1,277,541.00. Following the completion of the transaction, the senior vice president now directly owns 20,230 shares of the company’s stock, valued at approximately $4,534,149.90. This trade represents a 21.98 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. 11.10% of the stock is owned by corporate insiders.
Wall Street Analysts Forecast Growth
Check Out Our Latest Stock Report on Danaher
Danaher Stock Performance
Shares of DHR opened at $212.97 on Tuesday. The stock has a market capitalization of $152.21 billion, a P/E ratio of 40.33, a P/E/G ratio of 2.66 and a beta of 0.82. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.05 and a current ratio of 1.40. Danaher Co. has a 1 year low of $196.80 and a 1 year high of $281.70. The company’s fifty day moving average is $216.92 and its two-hundred day moving average is $238.13.
Danaher (NYSE:DHR – Get Free Report) last posted its quarterly earnings results on Wednesday, January 29th. The conglomerate reported $2.14 earnings per share (EPS) for the quarter, hitting the consensus estimate of $2.14. Danaher had a net margin of 16.33% and a return on equity of 10.82%. During the same quarter in the previous year, the company earned $2.09 earnings per share. On average, sell-side analysts predict that Danaher Co. will post 7.63 earnings per share for the current year.
Danaher Increases Dividend
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, April 25th. Shareholders of record on Friday, March 28th will be given a $0.32 dividend. This is a boost from Danaher’s previous quarterly dividend of $0.27. The ex-dividend date of this dividend is Friday, March 28th. This represents a $1.28 annualized dividend and a yield of 0.60%. Danaher’s dividend payout ratio is presently 24.24%.
Danaher Company Profile
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.
Read More
- Five stocks we like better than Danaher
- The Most Important Warren Buffett Stock for Investors: His Own
- Quantum Gamble? Is IonQ’s Stock an Opportunity or a Mirage?
- Why Understanding Call Option Volume is Essential to Successful Options Trading
- 4 Stocks Raising Dividends by More Than 10%
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- Can SoundHound AI Double? What the Fundamentals and Deals Reveal
Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Co. (NYSE:DHR – Free Report).
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.